All In Biotech

Drug Trial Radar · NCT05156320

Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients With Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Apr 14, 2022

Primary completion

Dec 18, 2024

Study completion Dec 18, 2024

Sponsor

Lead sponsor
Scholar Rock, Inc.Industry
Sponsor type
Industry
First posted
Dec 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 trial (Study SRK-015-003) was conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and were receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam), to confirm the efficacy and safety of apitegromab as an adjunctive therapy to nusinersen and evaluate the efficacy and safety of apitegromab as an adjunctive therapy to risdiplam.

Conditions

  • Spinal Muscular Atrophy
  • Spinal Muscular Atrophy Type 3
  • Spinal Muscular Atrophy Type 2
  • SMA
  • Neuromuscular Diseases
  • Muscular Atrophy
  • Atrophy
  • Muscular Atrophy, Spinal
  • Neuromuscular Manifestations
  • Anti-myostatin

Interventions

  • ApitegromabDrug

    Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 was administered every 4 weeks by intravenous (IV) infusion.

  • PlaceboDrug

    Placebo was administered every 4 weeks by intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Efficacy Population: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score.Time frame: Baseline up to 12 months.

Locations

50 sites in 9 countries. Site status is shown where the registry gives one.

  • Children's of Alabama

    Birmingham, Alabama

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Children's Hospital of Los Angeles

    Los Angeles, California

  • Stanford University Medical Center

    Palo Alto, California

  • Rady's Children's Hospital/UCSD

    San Diego, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nemours Children's Hospital

    Orlando, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • The Johns Hopkins University

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Helen DeVos Children's Hospital

    Grand Rapids, Michigan

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • Columbia University, SMA Clinical Research Center

    New York, New York

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health & Sciences University

    Portland, Oregon

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • Children's Medical Center Dallas

    Dallas, Texas

  • University of Utah

    Salt Lake City, Utah

  • Children's Hospital of The King's Daughters

    Norfolk, Virginia

  • Seattle Children's Hospital

    Seattle, Washington

  • University of Wisconsin School of Medicine and Public Health

    Madison, Wisconsin

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Chr de La Citadelle

    Liège, Belgium

  • CHU Lille - Hôpital Jeanne de Flandre

    Lille, France

  • Hôpital Armand Trousseau, I-Motion

    Paris, France

  • CHU Toulouse - Hopital des Enfants

    Toulouse, France

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Dr. von Haunersches Kinderspital

    Munich, Germany

  • IRCCS Istituto Giannina Gaslini

    Genoa, Italy

  • A.O.U Policlinico G. Martino

    Messina, Italy

  • Foundation I.R.C.C.S. Carlo Besta Neurological Institute

    Milan, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.